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STRUCTURED ABSTRACT 
Background: Medicines non-adherence continues to be problematic in healthcare practice. 
After decades of research, few interventions have a robust evidence base demonstrating their 
applicability to improve adherence. Phenomenology has a place within the healthcare research 
environment. To explore the patients’ lived experiences of medicines adherence 
reported in the phenomenological literature? 
 
Method: A systematic literature search was conducted to identify peer-reviewed and 
published phenomenological investigations in adults, that aimed to investigate patients’ lived 
experiences of medicines adherence. Studies were appraised using the Critical Appraisal 
Skills Programme (CASP) Qualitative Research Tool. Thematic synthesis was conducted 
using a combination of manual coding and NVivo10 [QSR International, Melbourne] coding 
to aid data management. 
 
Results: Descriptive themes identified included i) dislike for medicines, ii) survival iii) perceived 
need, including a) symptoms and side effects and b) cost, and iv) routine. Analytic themes 
identified were i) identity and ii) interaction. 
 
 Conclusions: This work describes adherence as a social interaction between the identity of 
patients and medicines, mediated by interaction with family, friends, healthcare professionals, 
the media and the medicine itself. Healthcare professionals and policy makers should seek to re-
locate adherence as a social phenomenon, directing the development of interventions to exploit 
patient interaction with wider society, such that patients ‘get to know’ their medicines, and how 
they can be taken, throughout the life of the patient and the prescription. 
 
Keywords: medicines adherence, treatment compliance, phenomenology, social 
pharmacy, qualitative research, thematic synthesis 
 
Introduction 
Medicines adherence, defined as ‘how well a patient takes their prescription medicines’, 
continues to be problematic in healthcare practice.1 After decades of research, there is little 
consensus on improving poor adherence or tackling non-adherence.1, 2 Current approaches to 
research have resulted in numerous ways of measuring adherence, such as self-reported 
questionnaires, pill counts, and electronic packaging with more recent advances adding 
stomach-acid-activated microchips to medication dosage forms.1, 3 This has arguably led to 
multiple conceptualisations of the phenomenon, and has resulted in semantic confusion, from 
concordance, to compliance, to adherence. Often differences between definitions relate to 
varying degrees of patient-centred care, with changes often relating to how the patient ‘fits 
 into’ the phenomenon, ranging from following the prescriber’s orders, agreeing with the 
prescriber’s decisions, and or making decisions supported by a prescriber, respectively.4 
 
Methods of measuring adherence are heterogeneous, this has resulted in multiple 
conceptualisations of adherence, for example Hess, Raebel, Conner, Malone 5 reviewed 
measures of adherence that were based on the number of times a medicine was collected from a 
pharmacy, this demonstrated a number of calculations that could be used to measure 
adherence and conceptualised ‘adherence to medicines’ as a function of prescription 
collection, that is to say that collecting the medicine from a pharmacy inferred patients’ 
adherence to taking the medicine. Conversely van Onzenoort, Neef, Verberk, van Iperen, de 
Leeuw, van der Kuy 6 investigated a product that measured adherence at the date and time a 
product was popped from its blister packaging, adherence here then is conceptualised as 
something precise, to do with using medicines at the right date and time, and represents a 
different way of thinking about adherence compared to Hess, Raebel at al. (2006), rather than 
‘adherence’ meaning collecting a prescription once a month, ‘adherence’ becomes much more 
onerous, a set of behaviours enabling repetitive tasks to be carried out. In studies that use 
questionnaires, self-reports or interviews, adherence is measured as a function of the 
participants’ memory (i.e. being able to remember that they had taken their medicines as they 
were prescribed) as well as being influenced by participants’ own understanding of ‘what it 
means to be adherent’, that is to say, for some people missing a medicine by a few minutes is 
non-adherence, for others taking it within a few hours is still adherent. The variation in self 
report measures has been demonstrated to over-estimate adherence, suggesting these 
measures never to be used alone.7 Whilst it is well recognised no single method is preeminent 
and multiple methods of measuring the same phenomenon offer an element of triangulation and 
validity,8 these methods unintentionally conceptualise adherence as an epistemologically 
different phenomenon; as a representation of an ability to collect prescriptions once a month 
including elements of planning, and access to pharmacy services determined by wider, socio 
geographic determinants; as a representation of patient-specific, repetitious objective 
behaviours located at the right time and date and finally; as a representation of patients’ own 
subjective beliefs about their behaviours when under investigation in research. These different 
conceptualisations of the functions of adherence, representations of adherence or ‘ways of 
thinking about adherence’ may have inhibited the understanding of adherence from moving 
forward. A significant majority of research investigating adherence is conducted within the 
quantitative, positivist paradigm. This paradigm relates to an underpinning ideology of what 
reality is and how reality can be experienced. Positivism describes reality as posited – 
essentially this means that reality and truth are ‘out there in the world’ waiting to be 
discovered. Positivist approaches often use quantitative methods to discover, identify and prove 
truths that exist ‘out there in the world’ waiting to be discovered. However, due to the nebulous 
nature of the adherence phenomenon (is it a belief, an attitude, a short-term behaviour or a 
long-term set of behaviours?) using a positivist approach might overlook essential aspects of 
what it is actually like to experience the phenomenon, thereby limiting how the phenomenon 
can be conceptualised and understood, measured and modified. An alternative approach to 
investigating the phenomenon may be required to deliver insights, generate new 
understanding, and direct practice. Qualitative research can provide an alternative approach, 
although disciplinary conventions, such as journal types and word length, can mean that 
research findings are not as pervasive in the field as they might be.9 Qualitative research 
includes multiple methods of data collection such as semi-structured or unstructured 
interviews; focus groups; ethnography; and observational studies.10 Qualitative research 
enables rich, detailed data to be collected and analysed, allowing novel perspectives to be 
generated and phenomenon to be explored at a fundamental level, ontologically and 
epistemologically. That is to say, qualitative research can help identify what a phenomenon ‘is’. 
The need for this kind of fundamental qualitative research has been systematically identified in 
the adherence literature 1, 2, 11. Within the qualitative paradigm, phenomenology is positioned as 
a method and theoretical framework, based on the philosophical works of Heidegger and 
Husserl. 12 The approach has developed over the last century to embody a method of research, 
which can appear far removed from the scientific biomedical paradigm.13 Phenomenologists 
argue that phenomena, such as medicines use, are constructed through conscious interaction 
between subjective humans and the objective physical world. Thus to understand phenomena, 
researchers must engage with those that have ‘lived’ through the phenomenon.12 Collecting data 
is concerned with uncovering what others have experienced through interviews and focus 
groups – as well as collecting ‘grey’ data from photography, poetry, and studying other 
artifacts.12 Data can be analysed through interpretative phenomenological analysis or 
descriptive 106 transcendental phenomenological reduction as well as more conventional 
thematic qualitative analysis.14 Phenomenology has a place within the healthcare research 
environment 15 with methods adopted by nurse researchers to add unique insights to the 
literature,14 in areas such as heart failure and HIV, using medical devices to deliver continuous 
positive airway pressure  (CPAP) and specific treatments, for example cholinesterase inhibitors 
in Alzheimer’s disease. 16-19 Phenomenological methods deliver insights into the ‘lived 
experience’ of healthcare phenomena of nursing, medical and pharmaceutical interest. 
Systematic reviews and meta-analysis are widely accepted by health professionals as a gold 
standard approach for pooling data from multiple studies. Formal statistical methods can 
quantitatively synthesise data from multiple sources in the literature, however where this is 
inappropriate, as is the case for qualitative data, a thematic or narrative synthesis can be an 
appropriate approach. 20 Thematic analysis of phenomenological research may provide insights 
into patients’ lived experiences of medicines adherence and direct future strategies for 
adherence interventions based on patient experiences. The aim of this systematic review was to 
explore patients’ lived experiences of medicines adherence reported in the phenomenological 
literature, through systematic review and thematic synthesis. 
 
Objectives 
 
To explore patients’ lived experiences of medicines adherence reported in the 
phenomenological literature. 
 
Methods 
Protocol and Registration 
 
This review follows PRISMA Guidelines for reporting systematic reviews.21 Methodological 
limitations were assessed following the CASP Qualitative Research Tool and summarised by 
i) medicines/health issue, ii) methods, iii) sample size, iv) sample characteristics, and iv) 
major findings.22 The review protocol is registered with PROSPERO [Registration number 
CRD42015029494]. 
 
Eligibility Criteria 
The criteria for selecting records for inclusion in the review were i) was a phenomenological 
investigation ii) was in adults (defined as 18 years and older) iii) was published in a peer 
reviewed journal iv) aimed to investigate the patients’ experiences of medicines adherence. 
 
Exclusion Criteria 
Excluded studies were not published in peer-reviewed journals; were not in adults; did not aim 
to investigate patients’ experience of medicines adherence and were not phenomenological 
investigations. 
 
Information Sources 
A systematic search was performed to identify phenomenological articles that investigated 
patients’ experiences of medicines adherence. CINAHL, PsychInfo, Web of Science, Sociological 
Abstracts, and MEDLINE were searched. Databases were searched individually 
146 using the keywords displayed in Table 1 below. Additional records were identified via the 
snowball method through personal libraries of the authors, professional research networks and 
searching the references of the included records. 
 Search 
As “adherence” is a relatively new term to describe medicines-taking behaviour, “concordance” 
and “compliance” were also used to identify articles. Database specific subject headings were 
used to broaden the search to include appropriately indexed subordinate subject headings. To 
focus the search to phenomenological inquiries “phenomen*” and “DE phenomenology” were 
added to the search strategy. Search terms were truncated, such as  “phenomen*”, to include 
phenomenological and phenomenology. The search was limited to the English language. 
 
Study Selection 
Titles and abstracts resulting from the database search were reviewed by the first author  (APR) 
and full-texts were retrieved for relevant articles or articles that did not provide enough 
information in the title or abstract. The full-texts of eligible articles were then systematically 
reviewed for information about patients’ experiences of medicines adherence. Articles that met 
the inclusion criteria were reviewed in their entirety using the CASP Qualitative Research Tool. 
 
Data Collection and Synthesis of Results 
Thematic analysis was conducted manually and with the use of Nvivo10 computer software 
[QSR International, Melbourne] to generate descriptive and analytical findings, according to the 
method outlined by Thomas and Harden.20 Data was gathered for coding from articles by 
 uploading full-text PDF files into an NVivo project, then coding the text within the PDFs at 
6 different nodes. Text that was included in the analysis related 169 to the findings of the study, 
including participant numbers, evidence tables, quotes, as well as reported findings that were 
within the text.20 When text in the abstract and discussion related to new concepts, this was also 
collected for coding. Nodes were clustered to generate descriptive themes and used to generate 
analytic themes. Coding was conducted iteratively by APR and verified through repeated 
discussions with the other authors, who had access to the full-text papers and NVivo coding 
reports to independently verify coding decisions. Analytic themes were generated through 
additional coding, reflection and discussion with all authors. Collected data was coded ‘line-by-
line’ to develop descriptive clusters, which were used to generate analytic themes which ‘go 
beyond’ the primary studies.20 Data was also collected from each study to tabulate i) 
medicines/health issue, ii) methods, iii) sample size, iv) sample characteristics, and v) major 
findings as shown in Table 1.24  
 
Risk of Bias in Individual Studies 
Phenomenological and qualitative research is inherently subjective and often accused of 
bias. In phenomenological methodology, researchers are advised to avoid bias through a 
process of bracketing previously held presuppositions, referred to as epoché, prior to 
the investigation. As per the CASP Tool, bias was assessed based on the documentation 
of a reflective or epoché by the study authors.23 
 
Summary Measures and Synthesis of Results 
Whilst there is not a principal summary measure, studies’ key characteristics and 
findings are summarised below in Table 1. 
 
Risk of Bias across Studies 
Risk of bias was not assessed formally across the studies. 
 
Additional Analysis 
No additional analysis was performed. 
 
Results 
Study Selection 
 
The search strategy identified 47 records of phenomenological investigations into medicines 
adherence. 25 records did not meet the inclusion criteria. 22 articles were reviewed in their 
entirety using the CASP Qualitative Tool and included in a thematic synthesis. 
 
Study Characteristics – size, Health Problem/Issue Investigated, Sample Characteristics  
The majority of studies were set within the context of HIV,19, 25-30 other conditions including 
sickle cell disease, 31 asthma,32, 33 tuberculosis,34, 35 mental health (including schizophrenia, 
depression),36-38 osteoporosis,39, 40 and diabetes.41 Two studies investigated the experience of 
adherence more generally 42, 43 and two studies in multiple diseases, such as patients with life 
long dependency on medicines44 and headaches.45 Five studies investigated the experience in 
women only 25, 29, 39, 41, 42 whilst no studies investigated the experience 211 of adherence 
specifically in men. 
Sample sizes varied within the studies included in this review. The lowest sample size was 1, 
whilst the highest sample size was 149. The median number of participants was 14. In 
qualitative research, theoretical data saturation often dictates sample size however 
phenomenology appears to offer flexibility concerning appropriate sample sizes and 
emphasises the depth of analysis.46 The majority of studies were from the US and Europe 
although there was a wide range of geographical locations including the UK, 31, 32 Belgium,44 
America,19, 25-27, 37, 43, 45 Denmark,36, 42 Canada,39, 40 Iran,28 Australia,30, 38, 41 South Africa,34 
Vietnam,29 Sweden,33 and Ethiopia.35 
 
Thematic Synthesis of Findings 
Descriptive Themes (Results of Individual Studies) 
The synthesis of results identified four descriptive themes. These were i) dislike of medicines, ii) 
survival, iii) perceived need including two sub-themes of a) symptoms and side-effects and b) 
cost, and iv) routine. 
 
i) Dislike of medicines 
Studies often reported a seemingly pre-predicative dislike for medicines engendered through 
fear of uncertainty,19, 25, 27, 33, 37, 38, 40, 42, 44 dependency,33, 37, 45 and illicit drug taking 38 tempered 
230 only by hope.28, 34 Uncertainty was often described as experiencing a lack of knowledge19, 28, 
32, 34, 36, 38-40, 42, 45 and related to patients accepting the biological causes of their illness30, 33, 35, 37 or 
adoption of natural or alternative therapies.27, 34, 35, 42, 45 Participants reported receiving 
knowledge,31, 39obtaining knowledge,19, 32 and being ‘convinced’ to use medicines.30, 40 
 
ii) Survival 
Survival, living and a readiness to adhere were reported extensively in the literature.19, 25-35, 37, 39 
This was described as patients’ ‘choosing to live’ and consequently being ready to adhere to 
treatment.27, 28, 30 Papers also described adherence as an experience of life-long commitment, 
highlighting the implications of routine, everyday life on long-term outcomes such as survival.19, 
39 
 
 iii) Perceived Needs 
This theme relates to the frequently stated experience of weighing up 241 the advantages and 
disadvantages of using a medicine in relation to beliefs about ‘need’27, 28, 32, 33, 37-39, 42, 45 and was 
constructed from two sub-themes. 
a. Symptoms and Adverse Effects 
Studies reported the experience of symptom relief, ‘getting better’ and the medicines ‘doing 
what it was meant to do’. Papers often recounted a negotiation between the symptoms of a 
disease and the adverse effects of the medicine. 27, 33-35, 38, 45 This relates to theme i) Dislike of 
medicines, in that adverse effects were often considered an inevitable part of the experience  of 
adherence. 
 
b. Cost 
Six papers reported that the risk benefit analysis included considerations of the cost of the 
medicine.32, 35, 38, 39, 44, 45 The cost of travel to access the medicine was also conveyed in these 
studies as central to the experience of adherence in contexts where access to medicines was 
limited geographically or financially through insurance-based healthcare models.35, 38, 44, 45 
 
iv) Routine 
Lifestyle,19, 25, 27, 28, 30-32, 34, 39, 40, 44, 45 time,19, 43, 45 memory,13, 15, 19, 20, 27, 40, 42, 47 and distraction44 
 were found to be components of the experience of an adherence routine. Papers reported task 
based activities and the storage of medicines as structural components of the experience,30, 43, 45 
as well as devices that might be used or prepared as part of the adherence experience.48 
 
Analytic Themes (Synthesis of results) 
The descriptive themes were analysed further to construct analytic themes, which attempt to 
‘go beyond’ the findings originally reported in the studies,20 and deliver insights in the 
experiences of a phenomenon that transcend the contexts of the primary research. The 
analytical themes identified were i) identity and ii) interaction. 
 
i) Identity 
Pharmaceutical objects were reported to exist within the experience of adherence as embodied 
actors within a phenomenological life-world. Medicines were characterised by their efficacy to 
relieve symptoms; cause adverse effects; with costs associated with access; storage 
requirements; and how they should be taken. These identifying features of a medicine 
represented structural components of the experience and are demonstrated in the quotes 
below. 
 
Most patients referred to penicillin as a ‘very powerful medication’ and this was demonstrated 
in their accounts that they believe that by taking the penicillin the threat and severity of getting 
serious infections would be reduced 31 For example, one participant considered his 
bisphosphonate to be a “minor medication...just more like supplements than medication” 40  
 
The identity of the medicines also appeared to inform the participant’s identity, as below, 
 
And I think when Prozac came out somehow the brand name…I think Prozac became 
synonymous with crazy. For a lot of people. And so, people would say, “oh well, they’re on 
Prozac37 
 
As informed by the identity of the medicine, the identity of the patient emerged as part of the 
experience of adherence as noted in this quote, 
 
Many participants expressed feelings, such as loss of identity, loss of roles within personal 
relationships and embarrassment in relation to their steroid treatment. Loss of identity 
included issues such as personality changes, feelings of ‘not being themselves’, being unable to 
fulfil their normal role within the family unit, or being perceived as different by friends or 
family.32 
 
 Patient’s identity and personal values influenced adherence as they constructed ideals of right 
and wrong and how to live a perceived healthy life. 
These young women were determined to pursue a healthy lifestyle and considered medicine 
use to directly conflict with their health-related values. One informant felt it was “wrong” to 
take medicine, and shared her holistic view of healthy living:  
 
”If you do the things, if you are healthy in your daily life, if you are less stressed out and stuff, 
then that makes it so that you have less of a need for medicine. Um. So I really try to avoid 
medicine, in every way”.42 
 
A seemingly pre-predicative dislike of medicines as part of the patient’s identity was 
renegotiated by perceptions of need, ultimately leading to the modification of the patient’s 
identity and their ability to survive. 
 
You know, I have been on medication now for 8 years and it’s [sic] such a part of my life and the 
knowledge, the simple knowledge that if I had not taken my pills I would’ve been dead by now is 
enough to keep me taking the pills. I am healthy as anything. I’d probably never 303 been as 
healthy as I am  right now but live and I assume I’d be dead so… 30 
 
Identities of patients and of medicines appeared to be constructed through interaction with 
each other and wider social actors; this is expanded upon below. 
 
ii) Interaction 
Participants constructed identities of their medicines through interaction with their medicines; 
with healthcare professionals; with family members; the disease and with ‘healthcare 
literature’ (for example blood results and hospital charts). Instead of going to bars to find 
support, they began asking for this from their families, co-workers, healthcare providers and 
other HIV-positive people who were felt to be interested in their individual well-being.2 Studies 
also reported interaction with medicines identities through health literature, In-depth research 
by participants paralleled the search for the ‘right’ health care provider and the ‘right’ HIV 
medication, and included activities such as reading magazines, looking for information about 
HIV treatment on the Internet, attending community HIV-related groups and listening to 
lectures about HIV disease26 and through interaction with the medicine itself, 
 
The metaphor that emerged from the data was Life in a Pill Bottle, which reflected the central 
focus of HAART in participants’ lives and describes the complex relationships that evolve 
between among the person, the medications and the virus.27 
 
These interactions formed such a significant part of the experience of adherence, they often 
resulted in changes to the perceived identity of the medicine, particularly in relation to how it 
 should be taken, which occasionally led to non-adherence, as demonstrated by the quote below, 
 
When I got out of the hospital, he (health care provider) was really giving up on me. I thought, 
‘Well, this is not the person I want caring for me’. I decided, well, I want to live so I need to find a 
new doctor, which I did. “I took them (the HIV medications) about two months and stopped 
because I did not like him (health care provider).”26 
 
Interaction between patients’ experience of symptom relief, adverse effects and their 
healthcare professional is demonstrated further in this quote, here the patient clearly modifies 
their medicines-taking to align with their beliefs about steroids,  
 
I would be on my knees rather than take them, as time goes on and how I feel within myself, if I 
feel that I’m starting to come round. I will cut them down and maybe the consultant has said 
stay on two tablets until I see you in four weeks, but if I feel okay I won’t stay on those two, I 
mean I probably will cut them down again, maybe I shouldn’t but…32 
 
Interaction with expert healthcare professionals facilitated the construction of knowledge 
relating to the identity of the medicine congruent with adherence and consequently informed 
beliefs about ‘need’, this is demonstrated in the quote below, 
 
“so then I started to feel better and I started actually to get involved in more self-help kinds of 
things and reading stuff that was critical of most of what I had experienced in the mental health 
system. They really try to convince you that the illnesses that you have are biological and that if 
you take the drugs and do what we think you need to do, then you’ll be okay.”,37  
 
The construction of knowledge through interaction was often described as ‘convincing’ or 
‘being convinced’ and related to the identity of the medicine including it’s perceived need to be 
taken, and the patients’ identity and in relation to how they should use medicines. This is 
 demonstrated below, 
 
 “[the GP] that she automatically put women on bone density medication once they were fifty or 
over...So I was not convinced to take it because...I wasn’t convinced that I needed it. Not at all.” 
She was then referred to a specialist who gave her an in-depth explanation of her condition and 
about the medication itself. Following the visit with her specialist, this participant decided to 
take osteoporosis medication: “I felt very confident and secure once I spoke with her [the 
specialist] in detail about my concerns taking the drug. I just didn’t want to take any drug unless 
it was necessary. But she explained everything so thoroughly and had information to back it up 
from my charts. So she convinced me and she said she doesn’t mainly prescribe drugs either, 
nor does she like taking them herself unless it’s necessary.” 40  
 
Bias was not assessed across the studies. 
 
Discussion 
 
Summary of Evidence 
The findings from this synthesis suggest that a structural component of adherence is the 
interaction between the distinct, textural identities of social actors. Adherence was experienced 
as a dynamic routine, informed by knowledge about the patient and about the patients’ 
medicines, that patients gained from wider society. This work describes important structures of 
adherence as identity, of patients and medicines, and as interaction between the patient, their 
medicine and wider social interaction with friends, family, and health professionals. Knowledge 
and perceptions, constructed from social interaction, enabled patients to modify medicines-
taking routines, ultimately resulting in normalised non 
adherence, i.e. patients ‘got to know’ their medicines to such an extent that they could 
confidently modify their medicine-taking routines despite prescribed regimens. 
 
This work supports that conducted using other approaches, which identified the importance of 
perceived need. 49 Horne et al. argue that internal negotiations between the patient’s perceived 
need of a medicine and the patient’s concerns about adverse effects position adherence as a 
dichotomy. This was also seen in the reviewed phenomenological literature, as perceptions of 
need and of survival were explicitly described in relation to medicines taking. The construction 
of knowledge about the safety and efficacy of medicines, and hence the need of medicines, is 
also supported by other work.50 Conceptualising medicines as social entities, as well as 
biochemical ones, is a well-supported position and supports the findings of this review, relating 
to the structures of adherence centred on social interaction.48, 51, 52 Particularly the work by 
Dingwall and Wilson, which reported the ‘symbolic transformation’ pharmacists perform when 
dispensing medicines, changing medicines from biochemical to social entities.53 Framing 
interactional relationships as significant parts of the adherence experience is also supported by 
other work.54, 55 This highlights the importance of initial support and reinforcement when 
medicines are first prescribed and crucially, throughout the life of the prescription.  
Relevance to HCPs and Position within Adherence Research 
For healthcare professionals, these findings highlight the importance of social interaction on 
constructed patient beliefs, lay knowledge about medicines, and experiences of adherence. In 
clearer terms, this work highlights patients’ interaction with wider society as domain for novel 
intervention development. Within this domain, healthcare professionals might consider their 
own role in generating patients’ perspectives of medicines’ identities, seeking to combine their 
scientific expertise with patients’ lay knowledge and encouraging patients to ‘get to know’ their 
medicines over repeated clinical interactions. This might help patients consider the long-term 
outcomes of adherence and ultimately encourage patients to identify 
adherence within the context of wider societal norms. This work 402 can be located within the 
adherence research as a novel perspective of the adherence phenomenon. Adherence 
researchers might use this work to direct novel intervention development that positions 
adherence as a function of wider social interaction. The UK’s National Institute of Health and 
Care Excellence’s (NICE) guideline on medicines adherence56 advocates that interventions are 
tailored to meet patients’ individual needs, with an emphasis on patients being given an 
appropriate amount of information to make an informed decision. The guideline does not 
appropriately recognise medicines as tacit social objects and medicines adherence as a social 
phenomenon, where information to make an informed decision is often generated through 
social interaction with lay sources of knowledge. Policy makers must consider the wider social 
determinants of adherence, such as exposure to information in the mass media, newspaper 
headlines, on the Internet and generated through interaction with healthcare professionals. 
Interventions to improve adherence should therefore utilise these forms of social interaction, 
promoting adherence through public health campaigns. Additionally health professionals could 
highlight the need to scrutinise information about medicines that patients may be exposed to 
from other social interaction, such as interactions with family and friends, encouraging patients 
to discern between robust, scientifically-informed medicines’ information and lay knowledge. 
 
The findings also support the use of phenomenology as a theoretical framework and method to 
investigate adherence. 
 
Limitations of this review 
Synthesis of qualitative data is often controversial as qualitative findings are often deeply 
 contextualised and so difficult to transfer from one setting to another. Thomas and Harden 
argue that “the act of synthesis could be viewed as similar to the role of a research user when 
reading a piece of qualitative research and deciding how useful it is to their own situation.” 20 
They go on to argue that context can be preserved if aims, methods, sample characteristics and 
settings of the manuscripts synthesis are shared as part of the synthesis, as in Table 1. 
 
Phenomenologists are encouraged to present their findings in creative and novel ways to 
engage wider public interest. Due to this varied nature of phenomenological research, it is 
possible some studies were not identified, such as those presented as art or poetry and not 
 published in journals. Limiting the study to include only phenomenological studies limits the 
generalizability of the findings, however this was felt an appropriate way to manage 
differences in conceptual frameworks, philosophies and theoretical backgrounds to different 
types of qualitative research, maintaining a sense of conceptual congruity between the included 
studies. The authors are currently unaware of a method for identifying or assessing quality of 
this type of publication systematically and consequently 437 could not include this work in the 
review or thematic synthesis. A further limitation of this review is that we only included studies 
that explicitly aimed to investigate the experience of medicines adherence. This meant that 
studies investigating only a part of the experience of medicines adherence, for example 
investigating beliefs about treatment, or studies investigating the broader experience of 
healthcare, such as self-management of diabetes, were excluded from the study. It could be 
argued that these excluded papers may have included relevant extracts however as their 
primary aim was not investigating the experience of adherence per se, these extracts may have 
been hard to identify or contentious in their relevance to adherence. 
 
Conclusion 
This work describes adherence as a social interaction between the identity of patients and 
medicines, mediated by lay knowledge constructed through social interaction with family, 
friends, healthcare professionals, the media and the medicine itself. Patients ‘got to know’ their 
medicines to such an extent that interactions with the medicine could be modified to 
 deviate from the prescription. Healthcare professionals and policy makers should seek to co-
construct patient beliefs about medicines, through repeated interaction with expert knowledge 
from healthcare professionals, the mass media and the product, such that patients ‘get to know’ 
their medicines and how they can be taken to improve health outcomes safely, i.e. are 
prescribed, throughout the life of the patient and the prescription. The systematic review of 
phenomenological investigations of medicines adherence has shown that the method can 
deliver novel insights across a range of disease states. Further empirical research is needed to 
support these findings. 
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